A phase I study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor targeted therapies

PURPOSE: The PI3K/Akt/mTOR pathway is dysregulated in metastatic renal cell carcinoma (mRCC). Buparlisib is a pan-PI3K inhibitor with activity in advanced solid tumors. The primary aim of this study was to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of buparlisib a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer
Autori principali: McKay, Rana R., De Velasco, Guillermo, Werner, Lillian, Bellmunt, Joaquim, Harshman, Lauren, Sweeney, Christopher, Rosenberg, Jonathan E., Hirsch, Michelle, Signoretti, Sabina, Van Allen, Eliezer, Walsh, Meghara, Vaishampayan, Ulka, McDermott, David F., Choueiri, Toni K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567751/
https://ncbi.nlm.nih.gov/pubmed/27198170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30056
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi